Company Overview and News

27
Sensex jumps over 261 pts on value-buying, Nifty reclaims 10,772

3h freepressjournal.in
Mumbai: Benchmarks snapped their two-session falling streak to finish with smart gains today, spurred by bargain hunting in recently-battered metal and bank stocks amid a rebound in global equities.
YESBANK 500325 INDUSINDBK RELIANCE 532648 YYBKY 533278 500470 TTST 532187 TATASTEEL TATLY HDB 500180 RIGD HDFCBANK CLNDY COALINDIA RLNIY

24
Global cues, RIL, banks lift Sensex 261 pts amid rising trade war fears; InterGlobe dips

3h moneycontrol
The market recouped its losses seen in the previous session, following the recovery in its global counterparts on Wednesday amid heightened fears of trade war between the world's largest two economies US and China.
YESBANK INDIGO 500325 PAH KMBKY INDUSINDBK IBN RELIANCE HCTHY 532648 YYBKY 539448 ICICIBANK 532187 HDB 532174 500180 RIGD HCLTECH KOTAKBANK 532281 HDFCBANK 500247 RLNIY

29
Sensex opens in green on value-buying, up 130 points

12h freepressjournal.in
Mumbai: The BSE Sensex rebounded over 130 points in opening trade today, reversing its two-session losing streak on value-buying in select blue-chips amid a strengthening rupee. Overseas, mixed trend at other Asian markets also influenced trading sentiments here.
BAJAJ-AUTO YESBANK AXB INDUSINDBK 532648 YYBKY 532977 BHRQY 532215 AXBKY 532454 AXBA 500470 TTST 532187 TATASTEEL TATLY AXISBANK BHARTIARTL

2
IndusInd Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532187 INDUSINDBK

25
Sensex closes 262 pts lower on global weakness after Trump escalates trade threats

2018-06-19 moneycontrol
The market closed sharply lower on Tuesday following correction in its global counterparts after the US President Donald Trump threatened to impose fresh tariffs on China.
500325 KMBKY INDUSINDBK IBN RELIANCE 532978 ICICIBANK BAJAJFINSV BAJFINANCE 532187 HDB 532174 500180 RIGD KOTAKBANK HDFCBANK BJJQY 500247 500570 TATAMOTORS 500034 RLNIY TTM

18
Sensex suffers more losses, down 148 points on global cues

2018-06-19 freepressjournal.in
Mumbai: Benchmark Sensex declined by over 148 points in early trade today, tracking a weak trend in global markets as the trade spat between the US and China intensified. Unabated capital outflows by foreign funds and profit-booking by retail investors too dampened sentiment.
BAJAJ-AUTO INDUSINDBK IBN 532977 533278 500182 ICICIBANK 532187 532174 HEROMOTOCO HRTQY CLNDY COALINDIA

39
Sensex, Nifty turn choppy on weak global cues                 

2018-06-18 freepressjournal.in
Mumbai: The BSE Sensex turned negative after opening 76 points higher in early session today amid weak global cues on rising concerns of a global trade war. The 30-share index was trading lower by 84.09 points, or 0.24 per cent, at 35,538.05. The gauge had gained 22.32 points in the previous session.
BHRQY 533278 532215 500470 532187 AXISBANK HEROMOTOCO 500570 BHARTIARTL TATAMOTORS CLNDY AXB INDUSINDBK IBN AXBKY 500182 532454 AXBA ICICIBANK TTST TATASTEEL TATLY 532174 HRTQY COALINDIA TTM

8
Depositories share info of firms with bourses on FDI limit

2018-06-18 freepressjournal.in
A red flag has been activated in HDFC Bank, Wonderla Holidays, IndusInd Bank, Ashapura Minechem, Cyient and S H Kelkar & Company,
ABBOTINDIA JVLAGRO INDUSINDBK 538268 519248 532187 ASHAPURMIN 527001 HDB 500180 HDFCBANK 500488 WONDERLA

8
Depositories share cos#39; info with exchanges on FDI limits

2018-06-17 moneycontrol
Depositories have shared information about activation of red flag and FDI limit breach related to 12 companies, including HDFC Bank, with the BSE and the NSE, according to notices. As per the separate notices issued by the two bourses, a red flag has been activated in HDFC Bank, Wonderla Holidays, IndusInd Bank, Ashapura Minechem, Cyient Ltd and S H Kelkar and Company.
ABBOTINDIA JVLAGRO INDUSINDBK 538268 519248 532187 ASHAPURMIN 527001 HDB 500180 HDFCBANK 500488 WONDERLA

8
Depositories share info on activation of red flag, breach of FDI limit with bourses

2018-06-17 thehindubusinessline
(PTI) Depositories have shared information about activation of red flag and breach of FDI limit related to 12 companies, including HDFC Bank, with the BSE and the NSE.
ABBOTINDIA ALNSE JVLAGRO INDUSINDBK 538268 519248 532187 ASHAPURMIN 527001 HDB 500180 HDFCBANK 500488 WONDERLA

28
Sensex falls 126 points following US Federal Reserve’s rate hike

2018-06-14 freepressjournal.in
Mumbai: Equities slipped back into the red today after a three-day winning run as investors turned cautious following US Federal Reserve’s rate hike. The BSE 30-share Sensex fell by 126.09, or 0.35 per cent to quote at 35,613.07 in early trade, with IT, PSU, oil and gas, teck, banking and realty indices trading in the negative zone.
500325 500820 AXB INDUSINDBK IBN RELIANCE ASIANPAINT 533278 532215 AXBKY 500182 AXBA ICICIBANK 532187 AXISBANK 532174 RIGD HEROMOTOCO HRTQY CLNDY COALINDIA RLNIY

48
Markets maintain uptrend; Fed takes focus

2018-06-13 freepressjournal.in
Mumbai: Markets gave up early gains but managed to end higher for the third straight session today, driven by robust buying in technology and healthcare stocks amid positive macro data.
BAJAJ-AUTO 532977 BHRQY 533278 532215 500470 532187 AXISBANK HDFCBANK HEROMOTOCO BHARTIARTL CLNDY YESBANK AXB INDUSINDBK IBN 532648 YYBKY AXBKY 500182 532454 AXBA ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 HRTQY COALINDIA

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...